NICE
NICE reform put on hold – for now
September 17, 2014Sales and Marketing Dillon, NHS, NHS England, NICE, market access, vba
The reforming of NICE has been put on hold as the watchdog believes more changes must be wrought to deal …
Cancer drug gains first early UK access grant
September 17, 2014Research and Development, Sales and Marketing Cancer, NICE, UK, keytruda, oncology, pin, promising
A new type of cell therapy for cancer has become the first to be deemed by the UK government as …
NICE seeks more trial data from pharma
September 10, 2014Medical Communications, Research and Development, Sales and Marketing David Haslam, NICE, Tamiflu, alltrials, transparency
NICE is calling on pharma to release more data so it can better assess the costs of new medicines.The watchdog …
Celgene rebuffed by NICE over cancer drug
September 9, 2014Sales and Marketing Abraxane, Cancer, Celgene, Gemzar, NICE, gemcitabine, nab-paclitaxel
In new draft guidance NICE says that Celgene’s Abraxane (nab-paclitaxel) taken with Lilly’s Gemzar (gemcitabine) should not be funded by …
NICE backs world’s most expensive medicine
September 4, 2014Sales and Marketing AGNSS, Alexion, England, NICE, aHUS, solaris
In a U-turn on its previous guidance NICE is now recommending that the £330,000 rare disease drug Soliris should be …
NICE: Cancer Drugs Fund must use our processes
September 3, 2014Medical Communications, Research and Development, Sales and Marketing CDF, Cancer, David Haslam, Kadcyla, NICE, Roche
NICE believes that the Cancer Drugs Fund should be aligned with its cost-effectiveness processes, after the government recently announced a …
NICE and market access: time for reform?
August 26, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bristol-Myers Squibb, NICE, Yervoy, reform
Earlier in the year, at the ABPI’s annual conference, the UK pharma lobby group released a new report suggesting that …
Charities ‘disappointed’ in NICE and Janssen
August 15, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, prostate
The Institute of Cancer Research and Prostate Cancer UK are both urging NICE and Janssen to ‘get their act together’ …
Storm brewing over Roche cancer drug price
August 8, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Haslam, Kadcyla, NICE, Roche, Yervoy, rejection
The Breakthrough Breast Cancer charity and England’s drug pricing watchdog NICE have both attacked Roche for not lowering the price …
ABPI president: NICE needs political reform
August 1, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Deepak Khanna, NICE, Pfizer, jonathan emms, vba
Jonathan Emms, the new president of the ABPI, is a man not shy about defending the rights of the UK …
NICE won’t back Revlimid in new setting
July 31, 2014Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma
NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …
NHS England’s Sovaldi fund: opening the floodgates?
July 26, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDG, NICE, Professor David Haslam, hep C, sovaldi
Whilst seemingly more and more barriers are being erected to slow down the adoption of new medicines, there is a …
NICE extends recommendation for Efient
July 24, 2014Sales and Marketing ACS, Efient, NICE, Plavix, longs ton, prasugrel
In updated guidance NICE has extended its recommendation of Efient (prasugrel) in combination with aspirin for preventing blood clots in …
NICE ‘yes’ for cancer drugs
July 23, 2014Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy
Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …
NICE ‘yes’ for Selincro
July 10, 2014Sales and Marketing Lundbeck, NHS, NICE, alcohol, nalmefene, selincro
Lundbeck has received a lift from UK drugs pricing watchdog NICE as it has recommended the firm’s alcohol dependency pill …
Latest content
FibroFind appoints Lee Borthwick as CEO
